高盛公司将智飞生物评级从中性上调至买进，目标价29元人民币。高盛公司将爱尔眼科评级从中性上调至买进，目标价15元人民币。

Group 1 - Goldman Sachs upgraded Zhifei Biological from Neutral to Buy, with a target price of 29 RMB [1] - Goldman Sachs upgraded Aier Eye Hospital from Neutral to Buy, with a target price of 15 RMB [1]